Abstract 277P
Background
Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, this seems too toxic for patients with frailty. Our study evaluated the efficacy and safety of tegafur/uracil (UFUR) associated with platinum and cetuximab (UPEx) in frail patients with R/M HNSCC.
Methods
Our study recruited frail patients who were aged > 70 years or performance status (PS) >2. Patients with a histologically confirmed R/M HNSCC unsuitable for locoregional curative therapy were treated with UPEx. The doses of UPEx were Tegafur 200mg twice per day for 14 days, cisplatin 30mg/m(2) at day 1 and cetuximab 500mg/m(2) at day 1, repeated every 2 weeks until progression or unacceptable toxicity. For patients with unfit renal function, carboplatin AUC =2 was used instead of cisplatin. The objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) was estimated.
Results
Forty-two patients were enrolled, including 81% aged > 70 years and 19% PS >2. The primary tumor mainly located in hypopharynx (43%) and oral cavity (43%), followed by oropharynx (10%) and larynx (4%). The ORR was 67%. Median OS and PFS were, respectively, 9.7 months (95% CI 7.4-11.9) and 5.8 months (95% CI 5.1-6.5). No patients had grade 3/4 adverse effects leading to discontinue treatment in our study.
Conclusions
The UPEx regimen was effective and tolerable as first-line treatment in frail patients with R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
The authors thank the heda and neck cancer working group at E-Da hospital for their great assistance of data reviewing and examining.
Legal entity responsible for the study
Meng-che Hsieh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session